Memorial Day! 45% Off Premium Subscription Claim Offer ⏰ 0d 00h 00m 00s

Information

611 Gateway Boulevard, Suite 900

South San Francisco CA 94080

650 278 8930

www.atarabio.com

Industry: Biotechnology

Sector: Healthcare

Atara Biotherapeutics

Description

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Click to get the best stock tips daily for free!
GOLDEN STAR
Ticker Change Signal Date
UAA
$5.84
11.64% May 09
IIPR
$54.61
1.70% May 09
HBM
$7.41
14.44% May 05
PODD
$257.01
24.90% May 02
GT
$9.14
21.77% Mar 21

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE